**NOT TO BE MISSED**

Clinical and Basic Research Papers – March 2009

Serge Ferrari, Editor-in-Chief
Ego Seeman, Clinical Editor
Hong-Wen Deng, Associate Editor
David G. Little, Associate Editor
Toshio Matsumoto, Associate Editor

Bone Modeling, Remodeling and Repair


Detailed analysis of the skeletal phenotype of CatK null mice reveals a 3- to 4-fold increase in osteoclast numbers on bone surfaces and elevated surface-based and total tissue-based bone formation rates (BFR), with a normal bone volume-based BFR. Hence decreased bone resorption in this model elicits some stimuli or prevents some inhibitory signals for OC proliferation and/or survival and does not reduce bone formation, thereby dissociating the cellular function of osteoclasts and matrix digestion from the coupling to osteoblasts. —SF

Clinical Studies and Drug Effects


This is an interesting study because it suggests there is a group of women who lose little or no bone with age. If this is the case, then the pathogenetic mechanisms need to be studied. Cauley et al. report that out of 8,224 subjects measured over 15 years, about 10% lost little or no BMD and these subjects exhibited a 20% lower risk of nonspine fracture and a 67% lower risk of hip fracture. Mortality risks were also lower. —ES


Following the release of the 2002 report of the Women’s Health Initiative (WHI) trial of estrogen plus progestin, the use of menopausal hormone therapy decreased substantially. The incidence of breast cancer also dropped thereafter, suggesting a cause-and-effect relationship between hormone treatment and breast cancer. However, the cause of this decrease remained controversial. This study demonstrates that the increased risk of breast cancer associated with the use of estrogen plus progestin declined markedly soon after discontinuation of combined hormone therapy and was unrelated to changes in frequency of mammography. —TM

Zoledronate (4 mg every 6 months) in addition to ovarian suppression by goserelin plus tamoxifen or an aromatase inhibitor, anastrozole, given for 4 years to pre-menopausal women with ER+ breast cancer, significantly improved disease-free survival (RRR, 36%) and non-significantly reduced the risk of death compared to endocrine therapy alone. Arthralgias, bone pain and fever were more common in the zoledronate groups, but no ONJ or serious renal toxicity were confirmed. Is this the basis for a revival of bisphosphonates in cancer treatment strategies? —SF


A 20-year-old female with autosomal dominant hypocalcemia (ADH) treated with PTH 1-34 continuously since age 6 is presented. Hypercalciuria and hypermagnesuria persisted despite normal or subnormal serum calcium and magnesium levels. Nephrocalcinosis developed by age 19. Cancellous bone volume was dramatically elevated but a bone mineralization defect was not improved. Thus, 14 years of PTH replacement in a child with ADH increased bone mass with little impact on mineralization, improved serum mineral control, but did not prevent nephrocalcinosis. This report demonstrates that PTH 1-34 replacement cannot reverse all the abnormalities in ADH, and gives important clues for the role of the CaR in bone mineralization and renal calcium/magnesium handling. —TM


These two papers report the effects of denosumab, the human monoclonal antibody against RANKL, in mice expressing a chimeric human-mouse RANKL gene. Osteoclast and osteoblast surfaces are modestly decreased even before treatment in these mice compared to wild-type, pertaining to a modest reduction of chimeric RANKL activity. The first study shows complete suppression of osteoclasts and inhibition of bone remodeling by denosumab in intact mice, leading to improved trabecular and cortical bone density and microarchitecture. The second study that compares denosumab to alendronate on transverse femur fracture healing shows delayed callus remodeling with both anti-resorptives, and a more significantly increased callus bone volume with denosumab. Both treatments improved mechanical properties after fracture repair. A commentary by D. Little that accompanies these two papers provides a detailed discussion of the implications of early anti-resorptives, particularly RANKL inhibitors, on callus biology and fracture repair. —SF
Genetics


Genome-wide association studies (GWAS) and other large-scale genetic association studies identify an increasing number of genes and SNPs associated with the risk of developing chronic diseases and their complications, including osteoporosis and fragility fractures. Now this study using a SNP chip (Affymetrix 500k) commonly used for GWAS examines the genetic structure of the European population, i.e., the relationship between the geographical origin of individuals (country/region of birth of their grandparents) and their genetic map. Those were closely correlated but started to markedly diverge between populations distant more than 500km (and sometimes less), and more so from North to South than East to West. Thus, in the case of a phenotype that is also strongly spatially structured, such as osteoporotic fractures, SNPs could appear to be associated with an increased risk of the disease not because of a true association between the two, but because both a few given SNPs and fractures are more prevalent in, say, Sweden than Portugal. Knowing that the SNP chip used here underrepresents rare alleles, which are even more likely to be both geographically segregated and prominently associated with disease, the risk of stratification may grow even further as new technologies will allow us to identify those rare SNPs more broadly. Hence, these results provide a strong caveat in the interpretation of GWAS based on geographically extended populations. —SF


This study reports a genome-wide association study on bone mineral density (BMD) in children. The Osterix (SP7) locus showed significant association with BMD. The authors conclude that genetic variants in the region of Osterix are associated with BMD in children and adults probably through primary effects on growth. —HWD

Molecular and Cell Biology


β-adrenoreceptor ligands stimulate bone resorption by enhancing expression of RANKL. β2-adrenoreceptor is expressed by bone cells. Noradrenaline and the selective agonists isoprenaline and salmeterol stimulated osteoclast formation and resorption in osteoblast co-cultures and increased expression of RANKL by osteoblasts. All three ligands enhanced RANKL-induced osteoclast formation and multinuclearity. There was no significant effect of noradrenaline or isoprenaline on osteoblast growth, differentiation or function. —ES

Secretion of the extracellular matrix proteoglycan versican is upregulated in many human tumors including lung carcinoma. Versican directly activates the TLR2 receptor and its co-receptors TLR6 and CD14 on macrophages, which in turn promotes tumor metastasis by producing TNF-α. Thus, cancer cells utilize signaling pathways of the innate immune system to generate an inflammatory microenvironment suitable for metastatic growth. —TM

Reviews, Perspectives and Editorials


Other Studies of Potential Interest


◆ Karagiosis SA, Chrisler WB, Bollinger N, Karin NJ. Lysophosphatidic acid-induced ERK activation and chemotaxis in MC3T3-E1 preosteoblasts are independent of EGF receptor transactivation. *J Cell Physiol*. 2009 Feb 2. [Epub ahead of print] [Abstract]


**Conflict of Interest:** Dr. Ferrari reports that he receives research support from Amgen and is an advisory committee member and lectures occasionally at conference symposia for Merck Sharp & Dohme, the Alliance for Better Bone Health (Sanofi Aventis/P&G), Amgen, Eli Lilly (Switzerland), Servier (Switzerland), and Novartis (Switzerland). Dr. Little reports that he receives royalties, research funds and consultancy fees from Novartis Pharma, as well as research support from Stryker Biotech. Dr. Seeman reports that he is an advisory committee member for Sanofi-Aventis, Eli Lilly, Merck Sharp & Dohme, Novartis, and Servier, and that he lectures occasionally at conference symposia for those companies. Dr. Matsumoto and Dr. Deng report no conflicts of interest.